We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+0.88%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$191M
AUM Growth
-$20.5M
(-9.7%)
Cap. Flow
-$12.4M
Cap. Flow
% of AUM
-6.5%
Top 10 Holdings %
Top 10 Hldgs %
8%
Holding
450
New
8
Increased
100
Reduced
215
Closed
125
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Brookfield Infrastructure
BIPC
|
+$1.03M |
| 2 |
OXLC
Oxford Lane Capital
OXLC
|
+$1,000K |
| 3 |
ECC
Eagle Point Credit Company
ECC
|
+$951K |
| 4 |
ORAN
Orange
ORAN
|
+$441K |
| 5 |
SNP
CHINA PETROLEUM & CHEMICAL CORPORATION ADS (REP 100 ORDINARY H SHARES)
SNP
|
+$424K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delek Logistics
DKL
|
+$2.13M |
| 2 |
Western Midstream Partners
WES
|
+$888K |
| 3 |
CNXM
CNX Midstream Partners LP
CNXM
|
+$744K |
| 4 |
OSB
Norbord Inc.
OSB
|
+$695K |
| 5 |
Marathon Petroleum
MPC
|
+$594K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.34% |
| 2 | Real Estate | 18.02% |
| 3 | Energy | 12.43% |
| 4 | Materials | 10.7% |
| 5 | Financials | 6.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Rhythm Pharmaceuticals
RYTM
$7.41B
| $333K | 0.17% |
15,384
-2,100
| -12% | -$48.1K |
|
|
KYNB
202
Kyntra Bio
KYNB
$28.2M
| $332K | 0.17% |
323
-44
| -12% | -$47.3K |
|
203
Geron
GERN
$930M
| $331K | 0.17% |
190,263
-25,936
| -12% | -$48K |
|
204
Bain Capital Specialty
BCSF
$833M
| $329K | 0.17% |
32,224
-4,571
| -12% | -$47.7K |
|
|
ICPT
205
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $322K | 0.17% |
7,774
+655
| +9% | +$30.1K |
|
206
Editas Medicine
EDIT
$402M
| $320K | 0.17% |
11,417
-1,570
| -12% | -$51.1K |
|
207
Prothena Corp
PRTA
$448M
| $318K | 0.17% |
31,875
-4,348
| -12% | -$52.3K |
|
208
Intellia Therapeutics
NTLA
$1.52B
| $317K | 0.17% |
15,927
-2,173
| -12% | -$45.3K |
|
209
Kodiak Sciences
KOD
$2.52B
| $315K | 0.17% |
5,316
-710
| -12% | -$35.6K |
|
210
BlackRock Debt Strategies Fund
DSU
$592M
| $313K | 0.16% |
31,521
-8,737
| -22% | -$86.2K |
|
211
Cytokinetics
CYTK
$10.8B
| $312K | 0.16% |
14,417
-1,971
| -12% | -$46.1K |
|
212
Gossamer Bio
GOSS
$100M
| $312K | 0.16% |
25,129
-3,425
| -12% | -$45.4K |
|
213
MeiraGTx Holdings
MGTX
$1.09B
| $309K | 0.16% |
23,357
-3,188
| -12% | -$42K |
|
214
Vir Biotechnology
VIR
$1.49B
| $309K | 0.16% |
9,001
-1,225
| -12% | -$52.7K |
|
|
KZR
215
DELISTED
Kezar Life Sciences
KZR
| $308K | 0.16% |
6,369
-869
| -12% | -$41.6K |
|
|
SYRS
216
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $308K | 0.16% |
3,484
-474
| -12% | -$53.9K |
|
217
Axsome Therapeutics
AXSM
$12.1B
| $304K | 0.16% |
4,269
-570
| -12% | -$44.4K |
|
218
Crinetics Pharmaceuticals
CRNX
$8.88B
| $304K | 0.16% |
19,371
-2,655
| -12% | -$40.6K |
|
219
CEL-SCI Corp
CVM
$21M
| $304K | 0.16% |
795
-109
| -12% | -$43K |
|
|
ATNX
220
DELISTED
Athenex, Inc. Common Stock
ATNX
| $304K | 0.16% |
1,255
-172
| -12% | -$41.3K |
|
|
BHVN
221
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $304K | 0.16% |
4,671
-647
| -12% | -$42.4K |
|
|
PHD
222
DELISTED
Pioneer Floating Rate Fund
PHD
| $301K | 0.16% |
29,832
-11,979
| -29% | -$119K |
|
|
APLS
223
DELISTED
Apellis Pharmaceuticals
APLS
| $300K | 0.16% |
9,947
-1,352
| -12% | -$40.4K |
|
224
Korro Bio
KRRO
$151M
| $297K | 0.16% |
309
-43
| -12% | -$46.2K |
|
225
Revolution Medicines
RVMD
$39.1B
| $297K | 0.16% |
8,538
-1,163
| -12% | -$32.2K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q3 2020 Portfolio in Review
As of Q3 2020, Virtus ETF Advisers held 450 positions worth $191M, down 9.7% from $211M the previous quarter. Its ten largest holdings account for 8% of the portfolio.
Virtus ETF Advisers withdrew a net $12.4M in Q3 2020, closing 125 positions and reducing 215 holdings. Its most notable exit was CNX Midstream Partners LP, an estimated $744K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 34% a quarter earlier, followed by Real Estate and Energy.
Against the trend, Virtus ETF Advisers opened a new position in Oxford Lane Capital worth $1.03M.
- Virtus ETF Advisers's largest Q3 2020 buy was Oxford Lane Capital: 46,671 shares worth $1.03M.
- Virtus ETF Advisers added most to Brookfield Infrastructure in Q3 2020, an estimated $1.03M increase.
- Virtus ETF Advisers's biggest Q3 2020 reduction was Delek Logistics, cutting an estimated $2.13M.
- Virtus ETF Advisers fully exited CNX Midstream Partners LP in Q3 2020, selling an estimated $744K.
- Virtus ETF Advisers's ten largest holdings make up 8% of its $191M portfolio in Q3 2020.
- Virtus ETF Advisers opened 8 new positions and closed 125 in Q3 2020.
- Virtus ETF Advisers's portfolio value fell 9.7% quarter-over-quarter to $191M.
Based on Virtus ETF Advisers's 13F filing for Q3 2020, filed 13 Nov 2020.